Editas Medicine, Inc.
EDITNASDAQHealthcare● Active
$2.68
$-0.04(-1.29%)
Market Cap$261883134
P/E Ratio—
52W High$4.537
52W Low$1.66
Editas Medicine, Inc. (EDIT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EDIT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.26
Est. -$0.30 · +13.3%
Revenue
$0.00B
Est. $0.01B · -55.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
EDIT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.30 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$0.30 | -$0.26 | +13.3% | $0.00B | $0.01B | -55.6% |
| ▲ Q1 FY2026 | Mar 9, 2026 | -$0.27 | -$0.06 | +77.8% | $0.02B | $0.01B | +196.3% |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$0.38 | -$0.28 | +26.3% | $0.01B | $0.01B | -10.8% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -$0.41 | -$0.63 | -53.7% | $0.00B | $0.00B | +97.0% |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.51 | -$0.43 | +15.7% | $0.00B | $0.00B | +559.7% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -$0.39 | -$0.55 | -41.0% | $0.03B | $0.00B | +4680.0% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$0.76 | -$0.75 | +1.3% | $0.00B | $0.03B | -99.8% |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.30
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$0.26
EPS Est.
-$0.30
EPS Surpr.
+13.3%
Revenue
$0.00B
Q1 FY2026
Mar 9, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.27
EPS Surpr.
+77.8%
Revenue
$0.02B
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$0.28
EPS Est.
-$0.38
EPS Surpr.
+26.3%
Revenue
$0.01B
Q3 FY2025
Aug 12, 2025Miss
EPS Actual
-$0.63
EPS Est.
-$0.41
EPS Surpr.
-53.7%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.43
EPS Est.
-$0.51
EPS Surpr.
+15.7%
Revenue
$0.00B
Q1 FY2025
Mar 5, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.39
EPS Surpr.
-41.0%
Revenue
$0.03B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
-$0.75
EPS Est.
-$0.76
EPS Surpr.
+1.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.70 | $-0.21 | $0.01 | 2 |
| Q3 FY2027 | $-0.99 | $-0.30 | $0.01 | 2 |
| Q2 FY2027 | $-0.90 | $-0.27 | $0.01 | 2 |
| Q1 FY2027 | $-0.89 | $-0.27 | $0.01 | 2 |
| Q4 FY2026 | $-0.80 | $-0.24 | $0.01 | 4 |
| Q3 FY2026 | $-0.30 | $-0.28 | $-0.24 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +13.3% | $3.00 | $3.04 | +1.33% |
| ▲ Q1 FY2026 | Mar 9, 2026 | +77.8% | $2.00 | $2.32 | +16.00% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +26.3% | $2.47 | $2.52 | +2.02% |
| ▼ Q3 FY2025 | Aug 12, 2025 | -53.7% | $2.20 | $2.29 | +4.09% |
| ▲ Q2 FY2025 | May 12, 2025 | +15.7% | $1.45 | $1.54 | +6.21% |
| ▼ Q1 FY2025 | Mar 5, 2025 | -41.0% | $1.76 | $2.05 | +16.48% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +1.3% | $2.91 | $2.88 | -1.03% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -18.8% | $4.68 | $4.11 | -12.18% |
Q2 FY2026+1.33%
Report Date
May 5, 2026
EPS Beat/Miss
+13.3%
Price Before
$3.00
Price After
$3.04
Q1 FY2026+16.00%
Report Date
Mar 9, 2026
EPS Beat/Miss
+77.8%
Price Before
$2.00
Price After
$2.32
Q4 FY2025+2.02%
Report Date
Nov 10, 2025
EPS Beat/Miss
+26.3%
Price Before
$2.47
Price After
$2.52
Q3 FY2025+4.09%
Report Date
Aug 12, 2025
EPS Beat/Miss
-53.7%
Price Before
$2.20
Price After
$2.29
Q2 FY2025+6.21%
Report Date
May 12, 2025
EPS Beat/Miss
+15.7%
Price Before
$1.45
Price After
$1.54
Q1 FY2025+16.48%
Report Date
Mar 5, 2025
EPS Beat/Miss
-41.0%
Price Before
$1.76
Price After
$2.05
Q4 FY2024-1.03%
Report Date
Nov 4, 2024
EPS Beat/Miss
+1.3%
Price Before
$2.91
Price After
$2.88
Q3 FY2024-12.18%
Report Date
Aug 7, 2024
EPS Beat/Miss
-18.8%
Price Before
$4.68
Price After
$4.11
Avg Beat Reaction+4.91%
Avg Miss Reaction+2.80%
Beat Rate5 / 8 quarters
Largest Move+16.48% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EDIT ends December
Editas Medicine, Inc. (EDIT) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.26 — beating the analyst consensus of $-0.30 by +13.3%. EDIT has beaten EPS estimates for 3 consecutive quarters. The next EDIT earnings date is expected around September 1, 2026.
Each quarter, investors track EDIT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EDIT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EDIT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EDIT earnings · 5 questionsEditas Medicine, Inc.'s next earnings report is expected around September 1, 2026. EDIT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EDIT historically reports after market close (AMC).
EDIT earnings datewhen is EDIT earningsEDIT next earnings datewhen does EDIT report earningsEDIT earnings calendar
▸ Source: FMP · Editas Medicine, Inc. SEC filings · US GAAP · Editas Medicine, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026